WP
ITCI

Woodline Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Woodline Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-123,750
Closed -$16.3M – 1090
2025
Q1 		$16.3M Buy
+123,750
New +$15.4M 0.11% 262
2023
Q4 		– Sell
-1,193,732
Closed -$62.2M – 689
2023
Q3 		$62.2M Buy
1,193,732
+1,001,176
+520% +$58.3M 0.73% 30
2023
Q2 		$12.2M Buy
+192,556
New +$12M 0.14% 183
2023
Q1 		– Sell
-392,030
Closed -$20.7M – 807
2022
Q4 		$20.7M Buy
392,030
+103,704
+36% +$5.2M 0.28% 100
2022
Q3 		$13.4M Buy
288,326
+160,984
+126% +$8.41M 0.19% 157
2022
Q2 		$7.27M Buy
+127,342
New +$7.22M 0.11% 213
2021
Q2 		– Sell
-294,285
Closed -$9.98M – 636
2021
Q1 		$9.98M Sell
294,285
-30,482
-9% -$1.06M 0.22% 118
2020
Q4 		$10.3M Buy
+324,767
New +$8.54M 0.27% 113

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Woodline Partners's ITCI Position: Q2 2025 in Review

Woodline Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 123,750 shares — an estimated $16.3M sold.

Woodline Partners first reported a position in ITCI in Q4 2020 and held it in 8 quarters. The position peaked at $62.2M in Q3 2023. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Woodline Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Woodline Partners sold 123,750 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $16.3M.
  • Woodline Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 8 quarters.
  • Woodline Partners's Intra-Cellular Therapies Inc. position peaked at $62.2M in Q3 2023.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.